NewYork-Presbyterian has deployed an AI tool that analyzes prenatal health records to flag patients at risk for postpartum depression before delivery, aiming to catch a condition tied to up to 20 percent of postpartum deaths earlier than standard screening allows.
The pivotal DERM-SUCCESS study found the FDA-cleared DermaSensor device helped primary care physicians correctly refer 91.4 percent of malignant skin lesions versus 82.0 percent without it, a 52 percent cut in missed skin cancer referrals.
Johnson & Johnson won FDA De Novo authorization for its AI-assisted OTTAVA robotic surgical system on July 22, 2026, giving Intuitive Surgical's long-dominant da Vinci platform its first serious multi-competitor challenge in soft tissue robotics in two decades.
STAT reported in May 2026 that doctors used an AI tool called the Biomedical Data Translator to identify an existing drug, klonopin, as a potential treatment for a newborn's ultra-rare genetic disorder after genome sequencing alone left no clear treatment path.
Sinai Hospital in Baltimore has deployed Prenosis' FDA-authorized Sepsis ImmunoScore, an AI tool that analyzes 22 clinical parameters to flag sepsis risk up to 24 hours before deterioration, part of a growing real-world rollout of the first AI diagnostic cleared specifically for sepsis.
Whoop's rollout of Blood Pressure Insights, an FDA-cleared ECG and AI-driven lab panels shows wearables pushing deeper into medical territory, even as physicians warn the wellness-versus-diagnostic line is getting blurry.
A study of 1,800 clinicians across five academic medical centers found AI ambient scribes saved doctors about 16 minutes of documentation time per eight-hour shift, modest gains that still translated into one extra patient seen every two weeks.
AbbVie announced a multi-year AI drug discovery collaboration with Iambic Therapeutics on September 21, 2026, aiming to speed the search for new small molecule medicines in immunology, neuroscience and oncology.
The FDA cleared Tempus AI's ECG-MR software to flag undiagnosed mitral regurgitation from routine electrocardiograms, aiming to catch a leaky heart valve condition long before symptoms force emergency imaging.
Stanford Medicine researchers led by James Zou published a Science paper on September 17, 2026, describing a 37,000-agent AI virtual biotech that independently proposed a lung cancer treatment strategy later validated by a real pharmaceutical trial.